Fen Xu

2.1k citations
76 papers · 1.4k indexed · 1 hit paper · h-index 21
Topics
Liver Disease Diagnosis and Treatment (16 papers)Pancreatic function and diabetes (14 papers)Adipose Tissue and Metabolism (13 papers)
Partner nations
ChinaUnited StatesSweden

In The Last Decade

Fen Xu

74 papers receiving 1.4k citations

Hit Papers

SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p ...20232026202420252023255075

Peers

Fen Xu
Comparison fields: 5 of 102
  • Epidemiology 515
  • Molecular Biology 486
  • Endocrinology, Diabetes and Metabolism 418
  • Physiology 414
  • Surgery 246
Replace Sung‐E Choi with:
Sung‐E Choi South Korea
Sabina Paglialunga Canada
Kenji Kasuno Japan
Bryce J. van Denderen Australia
Sun‐O Ka South Korea
Francesca Saba Italy
Xiaoxin X. Wang United States
M. Julia Brosnan United States
Mengyin Cai China
Stephan Winnik Switzerland
Fen Xu relative to Sung‐E Choi South Korea Sung‐E Choi's profile →
Citations per field
00.5×
Sung‐E Choi · 1×
Citations per year

Countries citing papers authored by Fen Xu

Since Specialization
Citations

This map shows the geographic impact of Fen Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fen Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fen Xu more than expected).

Fields of papers citing papers by Fen Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fen Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fen Xu. The network helps show where Fen Xu may publish in the future.

Co-authorship network of co-authors of Fen Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Fen Xu. A scholar is included among the top collaborators of Fen Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fen Xu. Fen Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 3
3 3
4 1
5 6
6 6
7 8
8 36
9 12
10 5
11 11
12 1
13 29
14 10
15 3
16 34
17 9
18 25
19 10
20 17

About Fen Xu

Fen Xu is a scholar working on Geriatrics and Gerontology, Endocrinology, Diabetes and Metabolism and Family Practice, having authored 76 papers that have together received 1.4k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (16 papers), Pancreatic function and diabetes (14 papers) and Adipose Tissue and Metabolism (13 papers). The work is most often cited by research in Geriatrics and Gerontology (197 citations), Endocrinology, Diabetes and Metabolism (418 citations) and Physiology (414 citations). Fen Xu has collaborated with scholars based in China, United States and Sweden. Frequent co-authors include Jianping Weng, Hua Liang, Mengyin Cai, Jianping Ye, Huanyi Cao, Zonglan Chen, Zhan‐Guo Gao, Jun Yin, Xiaobin Zheng and Chantal A. Rivera. Their work appears in journals such as PLoS ONE, Hepatology and Diabetes.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026